Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nemzeti Népegészségügyi Központ is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, PIHONAK, SARAH, and is situated within 1 distinct art unit. This reflects a highly focused prosecution profile with a single active case. The 1 distinct art unit involved indicates that the subject matter is concentrated within one technical division.
PIHONAK, SARAH is the busiest examiner, with 1 pending office action. This 1 action represents the total of 1 pending office actions currently active for the company. As the only 1 distinct examiner involved, PIHONAK, SARAH will be the sole person reviewing the Biotechnology & Pharmaceuticals filings. Practitioners should focus their strategy on the 1 pending office action and the specific tendencies of PIHONAK, SARAH. This 1 pending office action is the only matter currently requiring a response from the company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PIHONAK, SARAH | 1 | 61.4% | +42.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682627 | HEXAHYDRONAPHTHALEN-2-ONE DERIVATIVES FOR USE AGAINST A CORONAVIRUS INFECTION | PIHONAK, SARAH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682627 | HEXAHYDRONAPHTHALEN-2-ONE DERIVATIVES FOR USE AGAINST A CORONAVIRUS INFECTION | PIHONAK, SARAH | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682627 | HEXAHYDRONAPHTHALEN-2-ONE DERIVATIVES FOR USE AGAINST A CORONAVIRUS INFECTION | PIHONAK, SARAH | 1627 | §103§112 | Non-Final OA | — | Pending | Feb 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNemzeti Népegészségügyi Központ has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Sarah Pihonak has the most, with 1 of Nemzeti Népegészségügyi Központ's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.